Reisinger Raquel, Caragea Marc, Teramoto Masaru, Shipman Hank, Berry-Rieser Dennis, Oli Muna, Kendall Richard, Burnham Taylor, Conger Aaron, McCormick Zachary
Department of Human Genetics, Utah Center for Genetic Discovery, University of Utah, Salt Lake City, UT, USA.
School of Medicine, University of Utah, Salt Lake City, UT, USA.
Interv Pain Med. 2022 Feb 17;1(2):100073. doi: 10.1016/j.inpm.2022.100073. eCollection 2022 Jun.
Lumbosacral transforaminal epidural steroid injection (LTFESI) is a commonly performed intervention for treating radicular pain. While factors that predict pain improvement after LTFESI have been evaluated, minimal literature exists regarding predictors of functional improvement.
To identify factors that are associated with functional improvement at short-term follow-up after LTFESI.
Retrospective review of prospectively collected registry data.
Patients undergoing LTFESI at an academic spine center who completed an Oswestry Disability Index (ODI) questionnaire both pre-procedure and one to three weeks post-procedure.
The outcomes of interest were the proportions of patients who experienced a minimal clinically important difference (MCID) in function defined as ≥ 30% improvement in ODI score, as well as ≥ 10-point and ≥15-point improvement in ODI score.
Logistic regression analysis was performed to examine the associations of predictor variables to the ODI responder/non-responder outcome variable. The predictor variables for the analysis included: age, baseline ODI score, Charleston Comorbidity Index (CCI), payer type, prior lumbosacral spine surgery, pre-injection opioid use, two-level injections, bilateral injections, repeat injection, trainee presence during injection, immediate numerical rating scale (NRS) change post-injection. An odds ratio (OR) and its 95% confidence intervals (CIs) were calculated.
A total of 606 patients were included in the analysis. More than half of the patients (56.8%) reported a ≥7.1% improvement in ODI score, and about 30% reported a ≥30% improvement in ODI score. Approximately 36% and 20% of the patients reported ≥10-point and ≥15-point reductions in ODI score, respectively. Medicaid and Medicare payer type and pre-injection opioid use were significantly associated with a lower likelihood of ≥30%, and ≥15-point improvements in ODI, after adjusting for the other factors ( < 0.05).
When using various common definitions of MCID for ODI score improvement, Medicaid, Medicare, and pre-injection opioid use were identified as factors that are negatively associated with functional improvement at short-term follow-up after LTFESIs.
腰骶部经椎间孔硬膜外类固醇注射(LTFESI)是治疗神经根性疼痛的一种常用干预措施。虽然已经对预测LTFESI后疼痛改善的因素进行了评估,但关于功能改善预测因素的文献却很少。
确定与LTFESI后短期随访功能改善相关的因素。
对前瞻性收集的登记数据进行回顾性分析。
在一家学术性脊柱中心接受LTFESI的患者,他们在术前和术后1至3周均完成了Oswestry功能障碍指数(ODI)问卷。
关注的结果是功能上经历最小临床重要差异(MCID)的患者比例,MCID定义为ODI评分改善≥30%,以及ODI评分改善≥10分和≥15分。
进行逻辑回归分析,以检验预测变量与ODI反应者/非反应者结果变量之间的关联。分析的预测变量包括:年龄、基线ODI评分、查尔斯顿合并症指数(CCI)、支付方类型、既往腰骶部脊柱手术、注射前使用阿片类药物、两级注射、双侧注射、重复注射、注射时实习医生在场、注射后即时数字评定量表(NRS)变化。计算比值比(OR)及其95%置信区间(CI)。
共有606例患者纳入分析。超过一半的患者(56.8%)报告ODI评分改善≥7.1%,约30%报告ODI评分改善≥30%。分别约36%和20%的患者报告ODI评分降低≥10分和≥15分。在调整其他因素后,医疗补助和医疗保险支付方类型以及注射前使用阿片类药物与ODI改善≥30%和≥15分的可能性显著降低相关(P<0.05)。
当使用ODI评分改善的各种常见MCID定义时,医疗补助、医疗保险和注射前使用阿片类药物被确定为与LTFESIs后短期随访功能改善呈负相关的因素。